These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25045284)

  • 21. Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer.
    De B; Lowenstein LM; Corrigan KL; Andring LM; Kuban DA; Cantor SB; Volk RJ; Hoffman KE
    MDM Policy Pract; 2022; 7(2):23814683221137752. PubMed ID: 36405544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
    Daniell HW
    Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy: indications, methods of utilization, side effects and their management.
    Magee DE; Singal RK
    Can J Urol; 2020 Feb; 27(27 Suppl 1):11-16. PubMed ID: 32101695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.
    Lomax AJ; Parente P; Gilfillan C; Livingston PM; Davis ID; Pezaro C
    Intern Med J; 2016 Feb; 46(2):141-8. PubMed ID: 25732203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indications and Complications of Androgen Deprivation Therapy.
    Fankhauser CD; Wettstein MS; Reinhardt M; Gessendorfer A; Mostafid H; Hermanns T
    Semin Oncol Nurs; 2020 Aug; 36(4):151042. PubMed ID: 32773255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
    BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.
    Siebert AL; Lapping-Carr L; Morgans AK
    Eur Urol Focus; 2020 Nov; 6(6):1170-1179. PubMed ID: 32690473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
    Klotz L; Toren P
    Curr Oncol; 2012 Dec; 19(Suppl 3):S13-21. PubMed ID: 23355789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy for prostate cancer.
    Sharifi N; Gulley JL; Dahut WL
    JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complications of androgen deprivation therapy in men with prostate cancer.
    Chen AC; Petrylak DP
    Curr Oncol Rep; 2004 May; 6(3):209-15. PubMed ID: 15066232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy-associated vasomotor symptoms.
    Jones JM; Kohli M; Loprinzi CL
    Asian J Androl; 2012 Mar; 14(2):193-7. PubMed ID: 22286861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013.
    Myint ZW; Kunos CA
    Front Oncol; 2020; 10():1125. PubMed ID: 32760670
    [No Abstract]   [Full Text] [Related]  

  • 39. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone health and prostate cancer.
    Saylor PJ; Smith MR
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.